uPM3, a new molecular urine test for the detection of prostate cancer
- 1 August 2004
- Vol. 64 (2), 311-315
- https://doi.org/10.1016/j.urology.2004.03.052
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate CancerEuropean Urology, 2003
- Proenzyme psa for the early detection of prostate cancer in the 2.5–4.0 ng/ml total psa range: preliminary analysisUrology, 2003
- Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task ForceAnnals of Internal Medicine, 2002
- Robustness of Free Prostate Specific Antigen Measurements to Reduce Unnecessary Biopsies in the 2.6 to 4.0 ng./ml. RangeJournal of Urology, 2002
- Repeat Prostate Biopsy: Who, How and When?: A ReviewEuropean Urology, 2002
- Large‐scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trialInternational Journal of Cancer, 2001
- Prostate-Specific–Antigen Testing for Early Diagnosis of Prostate CancerNew England Journal of Medicine, 2001
- THE USE OF TELOMERASE ACTIVITY FOR THE DETECTION OF PROSTATIC CANCER CELLS AFTER PROSTATIC MASSAGEJournal of Urology, 2001
- A PROSPECTIVE RANDOMIZED TRIAL COMPARING 6 VERSUS 12 PROSTATE BIOPSY CORES: IMPACT ON CANCER DETECTIONJournal of Urology, 2000
- Prostate Cancer Detection in Men With Serum PSA Concentrations of 2.6 to 4.0 ng/mL and Benign Prostate ExaminationJAMA, 1997